- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Modanifil use during pregnancy not tied to increased risk of fetal malformation: JAMA
Researchers at Sweden's Karolinska Institutet and the Norwegian Institute of Public Health have found in a large registers Study that there is no association between narcolepsy drug Modafinil and increased risk of malformation in babies born to mothers who had taken it while pregnant.
The study involving over two million pregnant women in Sweden and Norway is published in JAMA.
"This study is based on twice as many pregnancies as earlier studies, and we find no increase in the risk of malformation in infants exposed to modafinil during pregnancy," says the study's lead author Carolyn Cesta, researcher at the Centre for Pharmacoepidemiology at Karolinska Institutet's Department of Medicine in Solna.
Modafinil is used to improve wakefulness in adults with narcolepsy, MS-related fatigue and, sometimes, ADHD.
Larger than earlier studies
Earlier studies from countries such as Denmark have reported an increased risk of malformation in infants that were possibly exposed to modafinil while at the fetal stage of development. However, these studies were conducted on smaller populations and modafinil use is uncommon during pregnancy.
To discover more about the potential risks of modafinil use during pregnancy, researchers at Karolinska Institutet in Sweden and the Norwegian Institute of Public Health have now conducted a much larger study using data from each country's health registries.
Two million women in Sweden and Norway
The study is based on almost two million pregnancies between 2005 and 2017 in Sweden and Norway, and compared women who took modafinil from 30 days before conception to the end of the first trimester with women who did not take the drug at all.
A total of 133 (0.007 per cent) of the infants had had in-utero exposure to modafinil, and of them three (2.6 per cent) were born with a major malformation, as compared with 2.1 per cent of the non-exposed infants. This represents a relative risk of 1.06, a difference that is not statistically significant.
The researchers therefore draw the conclusion that there is no increase in the risk of malformation for infants exposed to modafinil during early pregnancy compared with non-exposed infants.
"Our results show how important it is to combine data sources, ideally from several countries, when examining the impact on a fetus of a drug that relatively few people use," says Kari Furu, senior researcher at the Norwegian Institute of Public Health and the study's last author.
for further references log on to:
http://dx.doi.org/10.1001/jama.2020.9840
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751